Moderna, Inc. (MRNA): Price and Financial Metrics
Moderna, Inc. (MRNA)
Today's Latest Price: $70.55 USD
Updated Sep 28 6:55pm
Add MRNA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
MRNA Stock Summary
- With a one year PEG ratio of 0.19, Moderna Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.35% of US stocks.
- MRNA's went public 1.81 years ago, making it older than just 3.13% of listed US stocks we're tracking.
- MRNA's price/sales ratio is 263.02; that's higher than the P/S ratio of 98.38% of US stocks.
- If you're looking for stocks that are quantitatively similar to Moderna Inc, a group of peers worth examining would be BNTX, ARGX, BGNE, DNLI, and FATE.
- MRNA's SEC filings can be seen here. And to visit Moderna Inc's official web site, go to www.modernatx.com.
MRNA Stock Price Chart Technical Analysis Charts
MRNA Price/Volume Stats
| Current price | $70.55 | 52-week high | $95.21 |
| Prev. close | $69.47 | 52-week low | $13.53 |
| Day low | $69.10 | Volume | 7,337,300 |
| Day high | $71.50 | Avg. volume | 17,723,109 |
| 50-day MA | $69.75 | Dividend yield | N/A |
| 200-day MA | $47.23 | Market Cap | 27.84B |
Moderna, Inc. (MRNA) Company Bio
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA
Loading social stream, please wait...